Compare · BIS vs HCXY
BIS vs HCXY
Side-by-side comparison of ProShares UltraShort Nasdaq Biotechnology (BIS) and Hercules Capital, Inc. (HCXY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIS and HCXY operate in n/a (n/a), so they compete in similar markets.
- HCXY carries a market cap of $4.49B.
- Over the past year, BIS is down 53.4% and HCXY is up 0.6% - HCXY leads by 54.0 points.
- HCXY has hit the wire 3 times in the past 4 weeks while BIS has been quiet.
ProShares UltraShort Nasdaq Biotechnology
The investment seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Latest BIS
Latest HCXY
- Hercules Capital Closes Institutional Notes Offering of $325.0 Million 6.300% Unsecured Notes due 2031
- Hercules Capital Prices Institutional Notes Offering of $325.0 Million 6.300% Notes due 2031
- Hercules Capital Announces Date for Release of Second Quarter 2026 Financial Results and Conference Call
- Hercules Capital Announces Date of 2026 Annual Meeting of Stockholders
- Hercules Capital Reports First Quarter 2026 Financial Results
- Hercules Capital Enters Next Phase of Growth with Expanded Leadership Team
- Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the First Quarter 2026
- Hercules Capital Announces Date for Release of First Quarter 2026 Financial Results and Conference Call
- Hercules Capital Sets New Record with All-Time High New Debt and Equity Commitments
- Hercules Capital Receives a BBB (high) Affirmed Investment Grade Corporate and Credit Rating from Morningstar DBRS